Turkish Journal of Medical Sciences
Volume 39

Number 6

Article 6

1-1-2009

The predictive role of AST level, prothrombin time, and platelet
count in the detection of liver fibrosis in patients with chronic
hepatitis C
ÖZLEM KANDEMİR
GÜRBÜZ POLAT
GÜLİZ SARAÇOĞLU
BAHAR TAŞDELEN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
KANDEMİR, ÖZLEM; POLAT, GÜRBÜZ; SARAÇOĞLU, GÜLİZ; and TAŞDELEN, BAHAR (2009) "The predictive
role of AST level, prothrombin time, and platelet count in the detection of liver fibrosis in patients with
chronic hepatitis C," Turkish Journal of Medical Sciences: Vol. 39: No. 6, Article 6. https://doi.org/
10.3906/sag-0902-11
Available at: https://journals.tubitak.gov.tr/medical/vol39/iss6/6

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

ORIGINAL ARTICLE

Özlem KANDEMİR1
Gürbüz POLAT2
Güliz SARAÇOĞLU1
Bahar TAŞDELEN3

Turk J Med Sci
2009; 39 (6): 857-862
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-0902-11

The predictive role of AST level, prothrombin time,
and platelet count in the detection of liver fibrosis in
patients with chronic hepatitis C
Aim: We aimed to assess the predictive value of a combination some of basic serum biochemical
markers for the diagnosis of clinically significant fibrosis in chronic hepatitis C.
Materials and Methods: Blood samples from 68 patients with chronic hepatitis C infection were
analyzed for aspartate aminotransferase, prothrombin INR, and platelet count. The liver
histopathology was evaluated using the Knodell protocol. The relationship between the serum
biochemical markers and severity of the stages were examined.
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Results: A strong association was found between the fibrosis stage and platelet count and GUCI (P
< 0.001, P = 0.035 respectively) but not APRI ([AST/ULN] / Platelet count [ ×109 /L]) × 100) (P =
0.052). The relationship between the platelet count <147 × 109 /L and the age, which is greater than
50, and severe fibrosis was significant (AUC = 0.779, P < 0.001). In this cut off value the negative
predictive value (NPV) and the positive predictive value (PPV) were 66.7% and 86.7%, respectively.
An index GUCI (Göteborg University Cirrhosis Index) was calculated using the AST, platelet count,
and prothrombin-INR. Using the cut of value 0.26, the sensitivity of this index was found as 58.33%
and the specificity 72.7% for diagnosis of severe fibrosis (stage 3-4); NPV and PPV were 76.2% and
53.8%, respectively.
Conclusion: Peripheral platelet count and GUCI can discriminate to some degree of accuracy
patients with severe fibrosis (stage 3-4) from those without severe fibrosis (stage 0-2).
Key words: Chronic hepatitis C, fibrosis, serum biochemical markers

Kronik hepatit C’li hastalarda karaciğer fibrozisinin
saptanmasında AST seviyesi, protrombin zamanı, ve trombosit
sayısının belirleyici rolü
Amaç: Kronik hepatit C’de bazı temel serum biyokimyasal testlerinin şiddetli fibrozisi tanımlamada
doğruluk derecelerini değelendirmeyi amaçladık.
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Yöntem ve gereç: Kronik hepatit C enfeksiyonlu 68 hastadan kan örnekleri aspartat minotransferaz,
protrombin zamanı ve trombosit sayısı için analiz edildi. Karaciğer histopatolojisi Knodell protokolü
kullanılarak değerlendirildi. Serum biyokimyasal belirleyicileri ve stage şiddeti arasındaki ilişki
araştırıldı.
Bulgular: Fibrozis derecesi ile trombosit sayısı ve GUCI arasındaki ilişki anlamlı bulundu (P < 0,001,
P = 0,035, sırayla), ancak APRI ile ([AST/ULN] / Trombosit sayısı [×109 /L]) × 100) (P = 0.052)
anlamlı bulunmadı. Trombosit sayısının <147 × 109 /L olması ve yaşın 50’nin üzerinde olması ile
ciddi fibrozis arasındaki ilişki anlamlı bulundu (AUC = 0.779, P < 0.001). Bu eşik değerde pozitif
prediktif değer ve negatif prediktif değer sırayla % 66,7 and % 86,7 olarak belirlendi. GUCI indeksi
(Göteborg University Cirrhosis Index) AST, trombosit sayısı ve protrombin zamanı kullanılarak
hesaplandı. Eşik değer bu indeks için 0.26 alındığında testin şiddetli fibrozisi saptamada sensitivitesi
% 58,33, spesifisitesi % 72,7, negatif prediktif değeri ve pozitif prediktif değeri sırayla % 76,2 and %
53,8 bulundu.
Sonuç: Periferik trombosit sayısı ve GUCI şiddetli fibrozisli hastaları (stage 3-4), fibrozisi şiddetli
olmayanlardan (stage 1-2) belirli bir doğruluk derecesinde ayırt ettirebilir.
Anahtar sözcükler: Kronik hepatit C, fibrozis, serum biyokimyasal belirleyicileri
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Introduction
One of the most important causes of chronic liver
disease is hepatitis C virus. It is estimated that overall
200 million people are influenced by this virus (1,2).
It leads to cirrhosis at the rate of 20% and to
hepatocellular carcinoma at the rate of 5%. Although
pegylated interferon and ribavirin combination
therapy produces permanent virological response in
over 50% of the cases, this is quite an expensive
treatment with important side effects. Moreover, only
a small proportion of the patients is eligible for
treatment or has access to treatment (3). Therefore,
establishing the indications for treatment accurately
is important. Although HCV genotype is one of the
most important factors determining the outcome of
treatment (4), the presence of severe fibrosis at the
onset of treatment is another factor with unfavourable
effect on treatment. In order to establish prognosis
and guide treatment, liver fibrosis should be staged
accurately (5). Liver biopsy is the gold standard for
staging. Unfortunately, because of the facts that this
procedure is invasive, it has complications, sampling
may be made inaccurately, pathological
interpretations are equivocal, and patients are
unwilling to undergo repeated biopsies following the
course of disease restricts its use (6,7).
Therefore, many investigators have been trying to
find noninvasive alternatives for the evaluation of
hepatic fibrosis, one of which is transient elastography
(FibroScan) (8). However, as the use of this
technology is expensive and its use is limited to
certain locations, investigations have focused on
serum biochemical tests, attempting to find direct and
indirect markers of liver fibrosis (9,10). Some of the
direct markers were combined in a panel, such as
FibroSpect, FibroMeter, HepaScore, and European
liver fibrosis test (1). Yet, these tests are neither cheap
nor available in many clinics. However, indirect
markers of fibrosis, such as aspartate
aminotransferase and the platelet count, are easily
available. So far, many laboratory tests, scores, and
indexes for indirect markers have been proposed for
noninvasive estimation of hepatic fibrosis in cases
with chronic HCV (11).
To this end, several indexes, such as aspartate
aminotransferase:alanine aminotransferase ratio
(AST/ALT), cirrhosis discriminant score (CDS), the
ratio of age to platelet (A/P), platelet count per se,
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Turk J Med Sci

Pohl score, the ratio of AST to platelet (APRI), the
ratio of the multiplication of AST with prothrombininternational normalized ratio (INR) to the count of
platelet, as known Göteborg University Cirrhosis
Index (GUCI), have been developed based upon
routine laboratory tests. Therefore, they can be used
easily in clinical practice. In the majority of the studies
on the subject, it has been reported that these tests
have acceptable accuracy in predicting severe fibrosis,
bridging necrosis, and cirrhosis. However, when the
these tests were evaluated in different study
populations, different outcomes were found.
The aim of the present study was to establish the
value of platelet count per se, APRI, and GUCI index
in predicting severe fibrosis in patients with chronic
hepatitis C.
Materials and methods
Sixty-eight chronic hepatitis C patients who were
admitted to the infectious diseases unit in our hospital
between 2005 and 2008 were included in this study.
All patients were tested positive for the presence of
HCV RNA using a polymerase chain reaction assay
(Cobas Amplicor HCV monitor; Roche Diagnostics,
Branchburg, N.J, USA), all tested positive for antiHCV antibodies, and they all hed increased serum
alanine aminotransferase (ALT) and aspartat amino
transferase (AST) values. None of the patients
demonstrated additional causes of chronic liver
diseases confirmed by standard clinical, serological,
biochemical, and radiological criteria. Additional
exclusion criteria were antiviral treatment before liver
biopsy, alcohol consumption in excess of 20g/d,
gastrointestinal bleeding in medical history, and
previous liver transplantation. To exclude the impact
of hypersplenism, patients with splenomegaly on
ultrasonographic evaluation and/or pancytopenia
were not included in the study.
The serum levels of ALT were studied by an
autoanalyser (Roche Cobas Integra 800, Roche
Diagnostics GmbH, Switzerland), platelet counts were
studied by a complete blood count analyzer (Sysmex
2100, Roche diagnostic GmbH, Sysmex, Switzerland),
and prothrombin –INR were studied with a
coagulameter (Dade Behring BCS, Siemens
Healthcare Diagnostics Inc, USA). From these routine
laboratory values, APRI and GUCI were calculated
exactly as originally described (11, 12).
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APRI = ([AST/Upper Limits of Normal (ULN)] /
Platelet count [ ×109 /L]) × 100
GUCI = Normalized ASTX prothrombin-INR ×
9
100 / Platelet count (×10 /L)
Liver tissue studies
After obtaining informed written consents,
percutaneous liver biopsy samples were obtained
using tru-cut needles. For routine histological
examination, all samples were fixed in 10% buffered
formalin, embedded in paraffin, and stained with
haematoxylin-eosin, trichrome, and Van-gieson. Liver
tissues obtained from chronic viral hepatitis were
scored as minimal (1–4), mild (5–8), moderate (9–
12), severe (13–18), and 0–4 according to the activity
and fibrotic index, respectively, using the
classification of chronic viral hepatitis described by
Knodell et al. (13).
Statistical methods
Statistical methods: MedCalc version 9.6.4 was
used for statistical analyses. Normality assumption
was checked by Shapiro Wilk test and Independent
sample t test was used to test statistically significant
differences between mean platelet values of stage
groups. Differences between stage groups according
to GUCI and APRI were evaluated using the MannWhitney U test. Cut off value for stage degree was
investigated by ROC analysis. Moreover, to show
efficiency of the cut off value for diagnosis, which
classifies the degree of stage into 2 distinct groups (02 and 3-4), sensitivity, specificity, NPV, and PPV
statistics and their confidence intervals were
calculated. Mean ± SD was used for descriptive
statistic of platelet and median (min-max) values were
used for descriptive statistics of APRI and GUCI. The
significance level was set at 0.05.
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Results
Overall 68 (26 male and 42 female) chronic
hepatitis C cases were included in the study. Mean age
of the cases was 52.6 ± 9.647 (27-74). Forty four cases
were in stage 0-2 and 24 cases in stage 3-4. Results of
the univariate analysis that were used to determine
the relation between stage and thrombocyte and
GUCI and APRI are shown in Table 1. In patients with
stage 3-4, platelet count was found to be significantly
lower (P < 0.001) and GUCI significantly high (P =
0.035), while no significant difference was found
between APRI and stage (P = 0.052). Then the cut off
points that may be of use in differentiating low stages
from high ones were determined for platelet and
GUCI. Sensitivity, specifity, NPV, and PPV values and
significance of these cut off points are presented in
Table 2. When determining cut off points for platelet,
age was taken into consideration and in those older
than 50, a significant relation was found between the
9
platelet value of 147 × 10 /L or lower and higher stage
(AUC = 0.779, P < 0.001). The relationship between
platelet count, age, and the stage of fibrosis is shown
in Figure 1 and ROC curve of the platelet count for
severity of fibrosis is shown in Figure 2. In addition,
cut off value for GUCI was established as 0.26 and
values over this were found to be significantly related
to stage (AUC = 0.665, P = 0.031). Box-plot chart of
the relationship between GUCI and fibrosis stage is
presented in Figure 3 and ROC curve of the GUCI for
severity of fibrosis is presented in Figure 2.
Discussion
In the present study, statistical significance of the
accuracy of APRI, GUCI and platelet count in
predicting the degree of liver fibrosis in chronic

Table 1. The difference between platelet count, GUCI, APRI, and stage of fibrosis in chronic hepatitis
C patients.
Stage
P
Patients (n)
Platelet count (109/L)
GUCI
APRI

0-2

3-4

44
204318.18 ± 53953.37
0.199 (0.066-1.178)
0.006 (0.0003-0.0780)

24
152291.66 ± 33932.77
0.267 (0.111-3.680)
0.0081 (0.0033-0.5700)

<0.001
0.035
0.052

Mean ± SD was used for descriptive statistic of platelet and median (min-max) values were used for
descriptive statistics of APRI and GUCI .
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Table 2. Cut-off values that were found for platelet count and GUCI, the sensitivity, specificity, AUC, PPV, NPV, and significance of these
tests.

Platelet (Age >50 years)
GUCI

Cut off

Sensitivity
(%)

Specificity
(%)

AUC

PPV
(%)

NPV
(%)

P

147X109/L
0.261

61.90 (38.5-81.8)
58.33 (36.7-77.9)

88.89 (65.2-98.3)
72.73 (57.2-85.0)

0.779
0.655

86.7
53.8

66.7
76.2

<0.001
0.031

260

100

240
220

80

180

Sensitivity

Platelet (x1000)

200

160

60

40

140

APRI
Stage 0-2

120
100
80

Stage 3-4
Age >50

0
20

40
60
100-Specificity

80

100

Figure 2. ROC curve of the platelet count, GUCI, and APRI for
severity of fibrosis.

Since fibrosis is the most important factor
influencing mortality and morbidity in liver diseases,
careful evaluation of fibrosis is necessary for early and
judicious treatment. Liver biopsy, which is an invasive
method, is still the gold standard in the diagnosis of
liver fibrosis. However, there are many problems with
the use of this method. Therefore, studies attempting
to determine the severity of liver diseases have
focused on noninvasive reproducible methods.

4.0
3.5
3.0
GUCI

platelet

0
Age <=50

Figure 1. The difference between platelet count, age, and stage of
fibrosis.

2.5
2.0
1.5
1.0
0.5
0.0
0-2

3-4
Stage

Figure 3. Box-plot graph of the difference between GUCI and
fibrosis stage.

hepatitis C cases was evaluated. Platelet count per se
and GUCI were found to be valuable in prediction
while APRI score was not found to be significant.
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In recent studies investigating the relationship
between platelet count and the severity of fibrosis in
CHC, it has been reported that peripheral platelet
count (PPC) reflects the severity of fibrosis in cases
with chronic hepatitis C (14-17). Similarly, it was
established in the present study that the decrease in
the number of platelets was related to increasing
degree of fibrosis.
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In the study of Islam et al. (17) it was emphasized
9
that when cut off value was taken as 190 × 10 /L for
platelet value irrespective of age, majority of cases
under this value had advanced fibrosis and cirrhosis.
Guannani et al. (18) reported that platelet count has
high diagnostic accuracy in predicting cases with
9
cirrhosis at a cut-off point of 130 × 10 /L. In the study
of Karasu et al. (16) no cut off point could be
determined for platelet and only PPC values were
reported to correlate negatively with age and severity
of fibrosis. In the present study, unlike the others, age
was taken into account when determining the relation
between the platelet count and the severity of fibrosis.
In those aged over 50, the relation between platelet
9
value of 147 × 10 /L or lower and high stage was
found to be significant. PPV of platelet count at this
cut off value was quite good (86.7%), suggesting that
the cut off value established had significant accuracy
in predicting severe fibrosis.
As cases without splenomegaly were included in
this study, the probability of this factor being cause of
thrombopenia was ruled out from the beginning.
Although thrombopenia was first correlated with an
increase in the autoantibodies to thrombocytes in
chronic hepatitis C cases, in a more recent study it was
demonstrated that thrombocytopenia could occur in
both CHB and CHC cases independent of etiology.
In another study, it was reported that in cases with
chronic hepatitis C, there is difference in thrombocyte
activation, which may partly account for
thrombopenia (19). However, at present it is thought
that the cause of thrombopenia in chronic hepatitis is
the decrease in thrombopoietin and other humoral
factors (they regulate megakaryocyte maturation and
thrombocyte production) resulting from decreased
hepatocyte mass accompanied by increased fibrosis
secondary to progressive liver damage (20,21).
Even though Wai et al. (22), who investigated the
relation between the severity of fibrosis and APRI
score and formulated as the ratio of AST to the platelet
count, reported its accuracy to be high in predicting
severe fibrosis and cirrhosis. In the study of Islam et
al. (17), as cited by Shahen and Myers in their
systematic review (1), NPV of this test yielded better
results than PPV and PPV yielded suboptimal values
(PPV 59%) only in units where these cases are
observed frequently. In the present study, although
APRI was established to be higher in severe fibrosis,
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the relation was not found to be significant. This may
be due to the fact that the number of our patients was
low and we had a different patient population.
Blood coagulation factors apart from factor VIII
are all produced by hepatocytes. Their serum half lives
are much shorter than that of albumin. Owing to
their rapid degradation, the measurement of
coagulation factors is one of the best indicators of liver
synthesis function and is beneficial for both
diagnosing liver parenchymal disease and evaluating
its prognosis. The most suitable measurement for this
purpose is serum prothrombin time, which provides
information on factors II, V, VII, and X (20). Islam et
al. (17) utilised combined prothrombin time
(prothrombin -INR) with APRI, and with the
resulting index (GUCI) observed improvement in
sensitivity, specificity, NPV, PPV, and ROC values of
the test. These investigators stated that biopsy should
not be carried out in those with GUCI score of <0.2 or
>4. With these cut off values, patients without
bridging fibrosis or having cirrhosis could be
distinguished. Another study supporting the benefit
of GUCI in determining the severity of fibrosis and
predicting the outcome of treatment in chronic
hepatitis C is that of Westin et al. (12). These
investigators demonstrated that under the cut off
value of 0.33, severe fibrosis and cirrhosis are not
present. Similarly, in the present study it was observed
that GUCI was useful in determining the severity of
liver fibrosis. Consistent with the results of Islam et
al., GUCI values over 0.26 were found to be
significantly correlated with high stage. When this cut
off value was considered, NPV was 76.2% and
specificity was 72.7%, whereas PPV and sensitivity
values were lower. For this reason we considered that
GUCI was a good parameter for exclusion of the
severe fibrosis. PPV value was found to be 53.8% and
this value is a suboptimal one for PPV. It is thought
that PPV value could be improved with different cut
off values that could be determined by increasing the
number of cases.
In conclusion, in the present study, it was
established in chronic hepatitis C cases that the
decrease in the number of platelets along with age was
important in determining the severity of liver fibrosis.
We thought that development of thrombopenia is
independent
of
splenic
enlargement
or
hypersplenism. In addition, it was also seen that APRI
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on its own was not adequate in determining the
severity of liver fibrosis and that GUCI score obtained
by the addition of prothrombin time to APRI might
help to determine the severity of fibrosis in untreated
cases. Such scores obtained through biochemical
parameters used in clinical routine practice may
obviate the need for liver biopsy in CHC cases.

Turk J Med Sci

However, such approaches are used infrequently in
clinical practice. This may be related to the fact that in
various studies diagnostic accuracy of the tests was
not considered adequate. It is our suggestion that
further studies with larger and more homogenous
patient groups should be carried out for wider use of
similar practices.
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